Melanoma and vitiligo: Immunology's Grecian urn

Cancer Immunology Immunotherapy

Volumn 42, Issue 5, 1996, Pages 263-267

  Berd, David ^a   Mastrangelo, Michael J ^a   Lattime, Edmund ^a   Sato, Takami ^a   Maguire Jr , Henry C ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOMA ANTIGEN;

AUTOIMMUNITY; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; MELANOCYTE; MELANOMA; PRIORITY JOURNAL; REVIEW; VITILIGO;

AUTOIMMUNE DISEASES; HUMANS; IMMUNOTHERAPY; MELANOMA; VITILIGO;

EID: 0029741539     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050280     Document Type: Review

References (56)

1. Al Badri AMT, Todd PM, Garioch JJ, Gudgeon JE, Stewart DG, Goudie RB (1993) An immunohistological study of cutaneous lymphocytes in vitiligo. J Pathol 170:149
2. Amoss MSJ, Ronan SG, Beattie CW (1988) Growth of Sinclair swine melanoma as a function of age, histopathological staging, and gonadal status. Cancer Res 48:1708
3. Bakker AB, Schreurs MW, Boer AJ de, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG (1994) Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179:1005
4. Berd D, Mastrangelo MJ (1988) Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Invest 6:337
5. Berd D, Murphy G, Maguire HC Jr, Mastrangelo MJ (1991) Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res 51:2731
6. Bleehen SS (1979) Histology of vitiligo. Pigment Cell 5:54
7. Bolognia JL, Pawelek JM (1988) Biology of hypopigmentation. J Am Acad Dermatol 19:217
8. Bystryn J-C, Rigel D, Friedman RJ, Kopf A (1987) Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 123:1053
9. Coit DG, Rogatko A, Brennan MF (1991) Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes: a multivariate analysis. Ann Surg 214:627
10. Copeman PWM, Lewis MG, Bleehen SS (1973) Biology and immunology of vitiligo and cutaneous malignant melanoma. Recent Adv Dermatol 3:245
11. Cui J, Bystryn J-C (1995) Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch Dermatol 131:314
12. Cui J, Harning R, Henn M, Bystryn J-C (1992) Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 98:162
13. Cui J, Chen D, Misfeldt ML, Swinfard RW, Bystryn JC (1995) Antimelanoma antibodies in swine with spontaneously regressing melanoma. Pigment Cell Res 8:60
14. Elder DE, Ainsworth AM, Clark WH Jr (1979) The surgical pathology of cutaneous malignant melanoma. In: Clark WH Jr, Goldman LI, Mastrangelo MJ (eds). Human Malignant Melanoma, Grune and Stratton, New York, p 55
15. Feeney-Burns L, Alspaugh M, Burns RP, Gao CL (1985) Uveitis in melanomatous swine: lack of evidence for humoral immune melanocyte destruction. Invest Ophthalmol Vis Sci 26:551
16. Hann SK, Im S, Bong HW, Park YK (1995) Treatment of stable vitiligo with autologous epidermal grafting and PUVA. J Am Acad Dermatol 32:943
17. Hara I, Takechi Y, Houghton AN (1995) Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 182:1609
18. Hertz KC, Gazze LA, Kirkpatrick CH, Katz SI (1977) Autoimmune vitiligo: detection of antibodies to melanin-producing cells. N Engl J Med 297:634
19. Hornung MO, Krementz ET (1974) Specific tissue and tumor responses of chimpanzees following immunization against human melanoma. Surgery 75:477
20. Houghton AN, Vijayasaradhi S, Bouchard B, Naftzger C, Hara I, Chapman PB (1993) Recognition of autoantigens by patients with melanoma. Ann N Y Acad Sci 690:59
21. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA (1994) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 91:3515
22. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella, E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458
23. Keats J (1820) Ode on a Grecian Urn
24. Koh HK, Sober AJ, Nakagawa H, Albert DM, Mihm MC, Fitzpatrick TB (1983) Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study. J Am Acad Dermatol 9:696
25. Lamont SJ, Smyth JR Jr (1981) Effect of bursectomy on development of a spontaneous postnatal amelanosis. Clin Immunol Immunopathol 21:407
26. Laucius JF, Mastrangelo MJ (1979) Cutaneous depigmentary phenomena in patients with malignant melanoma. In: Clark WH Jr, Goldman LI, Mastrangelo MJ (eds). Human Malignant Melanoma, Grune and Stratton, New York, p 209
27. Lerner AB, Shiohara T, Boissy RE, Jacobson KA, Lamoreux ML, Moellmann G (1986) A mouse model for vitiligo. J Invest Dermatol 87:299
28. McClay EF, McClay MET (1994) Tamoxifen: is it useful in the treatment of patients with metastatic melanoma. J Clin Oncol 12:617
29. McGregor BC, Katz HI, Doe RP (1972) Vitiligo and multiple glandular insufficiencies. J Am Med Assoc 219:724
30. Merimsky O, Shoenfeld Y, Yecheskel G, Chaitchik S, Azizi E, Fishman P (1994) Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism. Cancer Immunol Immunother 38:411
31. Milton GW, McCarthy WH, Carlon A (1971) Malignant melanoma and vitiligo. Australas J Dermatol 12:131
32. Mitchell MS, Nordlund JJ, Lerner AB (1980) Comparison of cell-mediated immunity to melanoma cells in patients with vitiligo, halo nevi or melanoma. J Invest Dermatol 75:144
33. Mitchell MS, Harel W, Kempf RA, Hu E, Kan-Mitchell J, Boswell WD, Dean G, Stevenson L (1990) Active-specific immunotherapy for melanoma. J Clin Oncol 8:856
34. Morton DL, Foshag LJ, Hoon DSB, Nizze JA, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R, Irie RF (1992) Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463
35. Mosher DB, Fitzpatrick TB (1994) Chemical leukoderma. In: Sober AJ and Fitzpatrick TB (eds). The Year Book of Dermatology, Mosby, St. Louis, p 3
36. Naughton GK, Eisinger M, Bystryn J-C (1983) Antibodies to normal human melanocytes in vitiligo. J Exp Med 158:246
37. Nordlund JJ (1987) Hypopigmentation, vitiligo, and melanoma. Arch Dermatol 123:1005
38. Nordlund JJ, Lerner AB (1982) Vitiligo: it is important. Arch Dermatol 118:5
39. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB (1983) Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 9:689
40. Nordlund JJ, Kirkwood J, Forget BM, Scheibner A, Albert DM, Lerner E, Milton GW (1985) Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res 45:1855
41. Oxenhandler RW, Berkelhammer J, Smith GD, Hook RR Jr (1982) Growth and regression of cutaneous melanomas in Sinclair miniature swine. Am J Pathol 109:259
42. Polak L, Turk JL (1974) Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature 249:654
43. Prehn RT, Prehn LM (1987) The autoimmune nature of cancer. Cancer Res 47:927
44. Richards JM, Mehta N, Ramming K, Skosey P (1992) Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10:1338
45. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319:1676
46. Schallreuter KU, Levenig C, Berger J (1991) Vitiligo and cutaneous melanoma. Dermatologica 183:239
47. Scheibenbogen C, Hunstein W, Keilholz U (1994) Vitiligo-like lesions following immunotherapy with IFNα and IL-2 in melanoma patients. Eur J Cancer 30A: 1209
48. Smith SB, Bora N, McCool D, Kutty G, Wong P, Kutty RK, Wiggert B (1995) Photoreceptor cells in the vitiligo mouse die by apoptosis - TRPM-2 clusterin expression is increased in the neural retina and in the retinal pigment epithelium. Invest Ophthalmol Vis Sci 36:2193
49. Song YH, Connor E, Li Y, Zorovich B, Balducci P, Maclaren N (1994) The role of tyrosinase in autoimmune vitiligo. Lancet 344:1049
50. Soong S-J (1992) A computerized mathematical model and scoring system for predicting outcome in patients with localized melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S-J (eds). Cutaneous Melanoma, Lippincott, Philadelphia, p 200
51. Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR, Doroshow JH, Aronson FR, Rubinstein LV, Mier JW (1993) Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 11:1969
52. Wayte DM, Helwig EB (1968) Halo nevi. Cancer 22:69
53. Wolkenstein P, Revuz J, Guillaume JC, Avril MF, Chosidow O (1995) Autoimmune disorders and interleukin-2 therapy: a step toward 'unanswered questions' (letter). Arch Dermatol 131:615
54. Wölfel T, Hauer M, Klehmann E, Brichard V, Ackermann B, Knuth A, Boon T, Meyer zum Büschenfelde K-H (1993) Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL). Int J Cancer 55:237
55. Woolfson H, Finn OA, Mackie RM, McQueen A, MacSween RNM (1975) Serum and anti-tumour antibodies and auto-antibodies in vitiligo. Br J Dermatol 92:395
56. Zachariae H, Zachariae C, Deleuran B, Kristensen P (1993) Autotransplantation in vitiligo: treatment with epidermal grafts and cultured melanocytes. Acta Derm Venereol (Stockh) 73:46